Capricor Therapeutics, Inc. (CAPR) Cash Flow Statement
Capricor Therapeutics, Inc. (CAPR) generated -$104.0M of operating cash flow over the twelve months to 2026-06-30, spent $25.8M on capital expenditure and had free cash flow of -$129.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CAPRCapricor Therapeutics, Inc.Follow CAPR — free
—
Price chart with a free account
- Market cap
- 344.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -4.6 | -2.2 | -6.1 | 1.0 | -10.8 | -14.5 | -14.2 | -13.9 | -6.8 | -10.1 | -16.8 | 4.9 | -25.6 | -40.0 | -69.8 | -104.0 | |
| Capital expenditure | 0.0 | 0.0 | 0.1 | 0.2 | 0.1 | 0.2 | 0.0 | 0.3 | 0.0 | 0.5 | 1.2 | 3.4 | 2.0 | 1.5 | 11.7 | -25.8 | |
| Free cash flow | -4.7 | -2.2 | -6.2 | 0.8 | -10.9 | -14.6 | -14.3 | -14.2 | -6.8 | -10.6 | -18.0 | 1.6 | -27.6 | -41.5 | -81.5 | -129.8 | |
| Share repurchases | — | — | — | — | — | — | — | — | 0.0 | 0.0 | — | — | — | — | — | — | |
| Stock-based compensation | 0.8 | 0.3 | 0.3 | 0.5 | 1.6 | 2.0 | 1.7 | 1.7 | 0.7 | 2.0 | 3.0 | 4.5 | 7.4 | 9.8 | — | — |
USD millions · SEC XBRL
Capricor Therapeutics, Inc. — questions
- What is Capricor Therapeutics, Inc.'s operating cash flow?
- -$104.0M over the twelve months to 2026-06-30.
- How much does Capricor Therapeutics, Inc. spend on capital expenditure?
- $25.8M over the twelve months to 2026-06-30.
- What is Capricor Therapeutics, Inc.'s free cash flow?
- -$129.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Capricor Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.